INVESTOR OVERVIEWCorporate ProfileRhythm is a biopharmaceutical company focused on developing and commercializing peptide therapeutics for the treatment of rare genetic deficiencies that result in life-threatening metabolic disorders. More >>Recent NewsMore >>10/10/17Rhythm Pharmaceuticals, Inc. Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares10/04/17Rhythm Pharmaceuticals, Inc. Announces Pricing of Initial Public Offering08/01/17Rhythm Expands Executive Leadership Team RYTM (Common Stock) $26.26 1.84 (7.53%)10/16/17 4:00 p.m. ETData provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and SourcesUpcoming EventsMore >>There are currently no events scheduled.